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Abstract
State immunization and cancer registries contain data that, if linked, could be used to monitor the 
impact of human papillomavirus (HPV) vaccine on cervical cancer and precancer. Michigan is 
uniquely positioned to examine these outcomes using two population-based resources: the state-
wide cancer registry and immunization information system (IIS).
We assessed the feasibility of identifying females in the IIS who had continuous Michigan 
residence and linking them to the cancer registry. We considered continuous residence necessary 
for future studies of vaccine impact to avoid misclassifying those who may have been immunized 
while residing out-of-state and whose immunization therefore may not have been reported in 
Michigan.
We identified females with 1976–1996 birthdates in the IIS and used probabilistic linkage software 
to match them with Michigan birth records. A stratified random sample of IIS-birth matches was 
provided to a commercial locator service to identify females with continuous Michigan residence. 
Cervical carcinoma in situ cases diagnosed in 2006 among females aged 10 through 30 years were 
also matched with the birth records; cancer registry-birth matches were merged with the IIS-birth 
matches using the birth record identifier.
Overall, 68% of the 1274,282 IIS and 61% of the 1358 cancer registry records could be matched 
with birth records. Among the sample of IIS-birth matches, most (86%) were continuous residents. 
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Seventy percent or more of cancer registry-birth matches merged with IIS-birth matches for cases 
born after 1984.
This is the first effort in the U.S. to show that linking records across IIS and cancer registries is 
practical and reasonably efficient. The increasing proportion of matches between the registries and 
live birth file with birth year, and the use of population-based data, strengthen the utility of this 
approach. Future steps include use of this method to examine incidence of cervical cancer 
precursors in HPV immunization-eligible females.
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1. Introduction
Monitoring human papillomavirus (HPV) vaccines post-licensure to assess immunization 
programs, evaluate policies, and demonstrate population impact is essential [1–5]. Cervical 
cancer, an outcome of HPV infection, may take several decades to develop [6]. Monitoring 
the incidence of high-grade pre-invasive cervical lesions is an attractive surrogate outcome 
because a decline in these lesions would be an early, reliable predictor of future declines in 
invasive disease [3,7]. Several surveillance networks monitor immunization impact on 
cervical cancer precursors; however, determining the immunization status of cases can be 
resource-intensive [3,8].
A 2014 report on accelerating HPV vaccine uptake by the President’s Cancer Panel indicates 
linking immunization and cancer registries would “enable study of the impact of HPV 
vaccination, including differences in rates of HPV-associated precancers and cancers 
between vaccinated and unvaccinated individuals” [9]. Michigan is well-positioned to 
monitor the population-level impact of HPV immunization on cervical lesions. The state’s 
immunization information system (IIS) includes HPV vaccine administration information 
and the statewide cancer registry conducts routine surveillance for invasive and in situ 
cervical cancers.
Our objectives were to assess the feasibility of identifying females in the IIS who resided in 
Michigan continuously from birth through 2006 and to develop a method to link their 
records to Michigan’s cancer registry. This method could be used in future studies to 
examine differences in the incidence of high-grade pre-invasive cervical lesions by HPV 
immunization status.
2. Methods
This study was approved by the Michigan Department of Community Health (MDCH) 
Institutional Review Board.
The three statewide population-based data sources used are described below.
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Immunization information system: The state’s IIS, the Michigan Care Improvement 
Registry, was created in 1998 as an electronic resource for confidential immunization data 
[10]. Through a linkage with Michigan’s Vital Records, the IIS has been continually 
populated with data, including a birth identifier number, for all Michigan live births after 
1993; therefore, the IIS contains a record for all Michigan-born residents born after 1993, 
regardless of immunization history. Providers can create records in the IIS for patients born 
out-of-state or before 1994. From its creation, providers were required to report all school-
exclusionary immunizations administered to persons born after December 31, 1993 and aged 
<20 years. Since August 2012, providers have been required to report all immunizations 
(including HPV and other immunizations not required for school entry) administered to this 
group. Providers have been able to electively report immunizations administered to persons 
aged ≥20 years since June 2006.
Cancer registry: The Michigan Cancer Surveillance Program participates in the Centers 
for Disease Control and Prevention (CDC) National Program for Cancer Registries and 
began tabulating cancer incidence reports statewide in 1985. All in situ cervical cancers 
(squamous carcinoma in situ [CIS] and glandular adenocarcinoma in situ [AIS]) have been 
reportable since 1985 [11]. Cervical intraepithelial neoplasia grade 3 (CIN3) cases were not 
reportable until 2009, and were therefore not included in this feasibility study. Both CIS and 
CIN3 lesions are consistently recognized by pathologists and, because they rarely regress 
and are at highest risk for progression to invasion, are considered true cancer precursors 
[12].
Birth file: Birthing facilities and attendants have been required to report each Michigan-
born infant to the MDCH since 1906. These reports comprise the Michigan birth file and 
include a unique birth identifier number with additional demographic information on the 
child and her parents.
For the purposes of this study, conducted in 2009, we identified (1) IIS records for all 
females aged 10 through 30 years as of December 31, 2006 and (2) cancer registry records 
for in situ cervical cancer cases diagnosed in 2006 among females aged 10 through 30 years. 
We considered a minimum age of 10 years to be sufficient for this feasibility study, because 
there were no in situ cervical cancer cases aged <15 years in the cancer registry. The most 
complete cancer registry data available at the time of the study were cases diagnosed in 
2006. Because HPV vaccine was not licensed until mid-2006, determination of HPV vaccine 
status was not a goal of this feasibility study.
2.1. IIS-birth file matching and cancer registry-birth file matching
Both IIS and cancer registry records can be linked to birth file records to obtain the birth 
identifier number, which can be used to link records across the IIS and cancer registry. The 
birth file is the only source of identifying information on the female’s parents, which is 
necessary to determine continuous Michigan residence, as described below. We considered 
continuous residence necessary for future studies of vaccine impact to avoid misclassifying 
those who may have been immunized while residing out-of-state and whose immunization 
therefore may not have been reported in Michigan.
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We established Michigan birth by separately matching the selected IIS records and the 
selected in situ cervical cancer records to those of females born between 1976 and 1996 (i.e. 
those aged 10–30 years in 2006) in the birth file using Registry Plus™ Link Plus version 
2.0, a no-cost probabilistic matching software package developed by the Centers for Disease 
Control and Prevention (CDC) [13]. In each set of matched files, records were first grouped, 
or blocked, by first name and birth year (i.e., these variables required an exact match). 
Variables probabilistically compared within blocks were last name, birth month and day, and 
address.
The matching software assigned a weighted match score to each potential record match. We 
reviewed potential matches to identify the score above which all matches should be 
considered conclusive and the score below which all matches should be considered invalid. 
We first sorted the result file in order of weighted match score. Then, starting with the 
highest matched score, when the reviewer (GC) identified the first record pair that, in his 
opinion, was a probable mismatch, the weighted match score for that record pair was used as 
the lower cut-off score for conclusive matches. Then, starting with the lowest matched score, 
when the reviewer identified the first record pair that was an acceptable match, the weighted 
match score for that record pair was used as the upper cut-off score for invalid matches. 
Matches between these two scores were considered potentially matched. For the IIS-birth 
file match, all record pairs with a match score of ≥14.8 were considered conclusive and 
those with a match score of ≤4.2 were considered invalid. For the cancer registry-birth file 
match, all record pairs with a match score of ≤2.0 were considered invalid. An upper score 
for the cancer registry-birth file match was not set because the small number of cases 
permitted manual review of all potentially matched pairs.
The final step was an intensive manual review of potentially matched record pairs with 
scores between the specified cut-off values to determine which matches should, in fact, be 
considered conclusive. Our review assessed the likelihood of a probable match based on 
fields that matched and degree of similarity between fields that did not match exactly, 
identifying minor misspellings, spacing differences, and other factors that caused two values 
to be deterministically different but judged a likely match.
To identify additional conclusive matches between cancer registry and birth file records, we 
manually evaluated all the potential matches with a score ≥2.0. Identifying additional 
conclusive matches between the IIS and birth file required an extra review step because 
reviewing all potential matches (>1 million record pairs) was too resource-intensive for our 
feasibility study. Instead, we manually examined a sample of 300 potential matches (4.2≤ 
score ≤14.8). To validate the matching process, we also manually examined 150 invalid and 
150 conclusive matches. As an additional validation, we conducted an assessment of direct 
IIS-birth file record linkages using the birth identifier number, available in IIS records of 
children born after 1993, by evaluating the percentage with a conclusive match score.
2.2. Merging cancer registry-birth file matches with IIS-birth file matches
Having matched records from both sources to the birth file, we used the birth identifier 
number to merge the records of Michigan-born in situ cervical cancer cases with the 
Michigan-born age-eligible females in the IIS (Fig. 1).
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2.3. Identification of continuous Michigan residence
Michigan residence since at least age 10 years will be necessary in future studies to assure 
that HPV immunizations and in situ cervical cancer cases would have been reported to both 
registries. The Lexis-Nexis® Accurint® record locator service [14] was used to determine 
continuous Michigan residence for a stratified random sample of the age-eligible females in 
the IIS whose records conclusively matched to the birth file. Accurint® data are derived 
from legal and financial transactions; access to these data are federally regulated and 
safeguarded by stringent privacy and security protections (www.lexisnexis.com/privacy). 
Records for 810 females were sampled from each of seven 3-year birth intervals (1976–
1978, 1979–1981, 1982–1984, 1985–1987, 1988–1990, 1991–1993, 1994–1996), for a total 
sample of 5670 females. Data submitted to Accurint included one record for each female, 
two records for her mother (one with name at the time of the birth, and one with maiden 
name), and a record for her father. Each record included first, middle, and last name, date of 
birth, and social security number (for the records of the mother and, if available, the father). 
For all record types, the mother’s address at the time of delivery was included. In total, we 
submitted four records for each female in the sample (with exceptions for births with no 
registered father and occasional records that did not provide the mother’s maiden name).
3. Results
3.1. IIS-birth file matching
Of the 1274,282 females aged 10–30 years as of December 31, 2006 in the IIS, we identified 
863,880 (67.8%) conclusive matches to the birth file; another 278,233 (21.8%) record pairs 
were possible matches (Table 1). Based on the sample of 150 invalid, 300 possible, and 150 
conclusive matches selected for manual review, all invalid matches were confirmed as non-
matches, and all conclusive matches were confirmed to be correctly matched. We 
determined that 103 of the 300 (34%) possible matches were correct, indicating a full 
manual review of all possible matches would have resulted in an additional 94,599 correct 
matches and increased the total correct matches to an estimated 958,479 (75%).
The proportion of conclusive matches increased with birth year. Whereas <50% of IIS 
records for females born from 1976 to 1978 matched to the birth file, >70% of records for 
females born after 1992 matched to the birth file. Ninety-eight percent of the age-eligible IIS 
records already containing the birth identifier number were conclusively matched with the 
birth file.
3.2. Cancer registry-birth file matching
Of the 1358 in situ cervical cancer cases, we identified 830 conclusive matches (61.1%) to 
the birth file (Table 1). Matching rates increased with year of birth, rising from <50% for 
females born before 1979 to ≥70% for birth years after 1983. The highest matching rate was 
78.6% for females born in 1989. There were few in situ cervical cancer cases with birth 
years in 1990 and 1991 (i.e., ages 15–16) and no cases were born after 1991.
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3.3. Merging cancer registry-birth file matches with IIS-birth file matches
Overall, 452 (54.5%) of the 830 cancer registry-birth file matches merged with an IIS-birth 
file match using the birth identifier number (Table 1). This percentage increased with birth 
year; overall, for cases born after 1984 >80% of cancer registry-birth file records merged 
with IIS-birth file records (70% for those born in 1985, increasing to 100% for those born 
after 1989).
3.4. Identification of continuous Michigan residence
In total, 21,542 records were submitted to Accurint containing demographic data for the 
random sample of 5670 age-eligible Michigan-born females from the IIS-birth file match 
(Fig. 1). For each female, we submitted one record with her own name and another record 
with the name of her mother at the time of birth. Additional records containing the mother’s 
maiden name were submitted for 5240 (92.4%) females, and records with the birth father’s 
name were submitted for 4962 (87.5%). Returned address histories contained up to 16 
separate addresses for mother, father, and child.
The ability to identify continuously resident females using Accurint varied by record type 
and birth year. The percentage of continuous residents found by only using the sampled 
female’s name was poor (14.1%). Using the mother’s name at the time of birth increased the 
continuous residency identification rates, ranging from 89.2% for females born 1976–1978 
to 99.1% for those born 1994–1996. Comparable identification rates were found when the 
father’s name (range: 89.6–98.2%) or mother’s maiden name (range: 81.9–98.1%) was used. 
Identification rates based on parental name increased with birth year of the sampled female. 
Overall, 4870 (85.9%) of the sampled Michigan-born females had an address history that 
indicated neither they, nor their mother or father, resided outside of Michigan during the 
female’s life.
4. Discussion
To our knowledge, this is the first U.S. study to assess the feasibility of creating a linkage 
between individual records in immunization and cancer registries. The feasibility of using 
cancer registry data to follow HPV vaccine cohorts has been demonstrated in Finland [15], 
and an HPV Vaccination Program Register with potential linkages to Papanicolaou 
screening test registry data has been developed in Australia [8,16]. Both Norway and 
Denmark have established linkages between their immunization registries and HPV-related 
clinical outcome data based on the presence of unique personal identification numbers that 
are assigned to every citizen and used across health registries [17,18]. Our work is the first to 
demonstrate a practical and reasonably straightforward methodology for linking existing IIS 
and cancer registry data in the absence of such an identifier, which is a much more common 
occurrence. The linkages across these data sources utilized freely available matching 
software (LinkPlus). This methodology will provide future opportunities for assessing the 
impact of HPV immunization on incidence of high-grade pre-invasive cervical lesions in a 
large, population-based cohort of Michigan residents.
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Data from the birth file were used to establish continuous Michigan residence among a 
sample of IIS-birth file matched records. Forty-six percent of Michigan-born in situ cervical 
cancer cases did not have corresponding records among the IIS-birth file matches. However, 
the percentage of Michigan-born in situ cases with corresponding records among the IIS-
birth file matches increased for younger cases, possibly due to increasing quality and 
completeness of information in the IIS over time commensurate with the implementation of 
the birth file linkage, permissive reporting for adults, and expanded reporting requirements 
for children. Overall, 86% of sampled IIS-birth file matches resided continuously in 
Michigan, indicating that we could expect a large proportion to be eligible for inclusion in a 
future study of vaccine impact.
There were limitations to these methods which have implications for future studies. First, 
our methodology will limit the analytic file to age-eligible females with records in the IIS 
that have resided continuously in Michigan since birth, in an effort to ensure that the cohort 
created is restricted to females with known HPV-immunization history. Females not born in 
Michigan, but who resided in the state continuously since they were age-eligible for HPV 
immunization, thus will be excluded, reducing statistical power to detect HPV immunization 
impact. In addition, females born before 1994 with no immunizations of any kind would not 
be included in the IIS because it was not populated with birth data before that year, which 
also would reduce the power of future studies. Third, because HPV immunization is not 
school-required (but, consistent with national guidance, is recommended for children age 11 
through 12 years, and may be given starting at age 9 years through age 26 years [19]) and 
may be administered to adults (for whom there is no reporting requirement), it may be 
under-reported in the IIS. Michigan’s public health code was recently revised to require all 
vaccines administered to those aged <20 years are reported to the IIS, not just those required 
for school; this change is very likely to increase HPV immunization reporting. Recent efforts 
to accept electronic immunization messages through health information exchanges should 
also improve completeness of reporting [20].
The effect of these limitations could be examined and addressed in future studies of vaccine 
impact. For example, samples of records that could not be linked to the birth file would be 
evaluated to determine the proportions that can be explained by birthplace. The 
encroachment of non-Michigan births into both datasets does follow an expected pattern of 
increasing with age, however.
Michigan is uniquely positioned to examine the impact of HPV vaccine on cervical cancer 
and precancer through linking state immunization and cancer registry data. The large sample 
sizes should provide sufficient power to detect differences in incidence of cervical cancer 
precursors for future studies, particularly given the high percentage of IIS-cancer registry 
linkages for females born after 1984. While most state cancer registries discontinued 
collection of in situ cervical cancers in 1996, Michigan remained the only state-wide 
population-based registry that continuously collected these data [11]; Kentucky and 
Louisiana re-instituted surveillance for cervical cancer precursors in 2010 [21]. The 
Michigan cancer registry has met the North American Association of Central Cancer 
Registries (NAACR) Gold Standard annually since 2002 (1999 data) [22]—the highest 
standard for completeness (>95%), accuracy, and timeliness [23]. In 2009, Michigan 
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conducted an audit of pathology reports from 10 randomly selected facilities and identified 
no missed cases of pre-invasive cervical lesions [21]. Additionally, the Michigan IIS is well-
populated, containing >97 million immunization records for 8.0 million individuals; >95% 
of Michigan children less than six years of age have two or more immunizations recorded in 
the IIS [24]. Michigan’s IIS has been a CDC IIS Sentinel Site since 2001, with minimum 
requirements including ≥85% vaccine provider enrollment and timely reporting for ≥90% of 
administered vaccines [25]. At the time of initial HPV vaccine licensure in 2006, the IIS was 
already well-populated with adolescent vaccine administration data [26]; 3-dose HPV 
vaccine coverage for Michigan females, as measured by the IIS, has been within the 
confidence limits of the CDC National Immunization Survey-Teen (NIS-Teen) estimates 
since Michigan-specific data were first reported [27]. In the 2013 NIS-Teen, the estimated 
proportion of girls aged 13 through 17 years who had completed the series was 34.5% 
(±9.4%) and the IIS showed coverage at 32.7%. In 2010, Michigan participated in an NIS-
Teen–IIS Match project. An IIS dataset for matched adolescents was compared to the 
vaccination data collected from immunization providers in the NIS-Teen. Weighted coverage 
with one or more and three or more doses of HPV vaccine for girls aged 13 through 17 years 
was 0.3% and 2.0% higher, respectively, using IIS data [MDCH unpublished data].
Future studies will be more easily implemented than the current feasibility study, for several 
reasons. First, birth data were used to populate the IIS starting in 1994, and we were able to 
conclusively match almost all IIS records having a numeric birth identifier to the birth file. 
Second, matching cases from the cancer registry to the birth file may have been hampered by 
name changes between birth and diagnosis; we observed higher matching rates for younger 
females. Beginning in 1997, social security numbers assigned to Michigan-born children 
became available as part of birth file data and can be used to augment the cancer registry-
birth file matching. Third, the completeness and comprehensiveness of the Accurint® 
address histories appear to have improved over time. Another study found this source of 
residential history has sufficient quality to suggest its routine use [28]. Our findings indicate 
this resource has become more complete and extensive since the mid-1990s.
Using existing registry data to assess the impact of HPV immunization on the incidence of 
cervical cancer precursors is feasible. Future steps include a study using IIS-cancer registry 
linked records to examine incidence of cervical cancer precursors in HPV immunization-
eligible females. This could include consideration of age at which the vaccine series was 
initiated, dose spacing, and total number of doses received. A similar methodology could be 
used in Michigan, or other jurisdictions with both high-quality IIS and in situ cervical cancer 
surveillance, to examine the population impact of HPV immunization on invasive cervical 
cancer and other HPV-associated cancers.
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Fig. 1. 
Design of a feasibility study to link cancer registry and immunization information system 
(IIS) records using vital records of live births, Michigan, 2006.
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